Ligand Pharmaceuticals Hits Day High with 9.91% Surge in Stock Price

Ligand Pharmaceuticals, Inc. has experienced a significant uptick in its stock performance, gaining 9.91% on November 6, 2025. The stock reached an intraday high of USD 211.91, showcasing its volatility and responsiveness to market dynamics.
In terms of performance metrics, Ligand Pharmaceuticals has outperformed the S&P 500 across various time frames. Over the past day, the stock's 9.91% increase contrasts sharply with the S&P 500's modest gain of 0.37%. The company has also shown impressive weekly and monthly performance, with increases of 12.84% and 15.05%, respectively. Over the past year, Ligand Pharmaceuticals has surged by 87.37%, significantly outpacing the S&P 500's 17.53% growth.

Despite these gains, the company faces challenges, including negative net profit and a low return on capital employed. The market capitalization stands at USD 3,250 million, categorizing it as a small-cap stock. Investors should note the company's ongoing financial struggles, including consecutive quarterly losses and a negative EBITDA, which may impact its long-term viability.